Similarly, cabozantinib, another multi-kinase inhibitor which targets MET, RET, AXL, VEGFR-2, and c-KIT, resulted in 6-month disease stability in 33% of relapsed osteosarcoma patients as monotherapy [188], and is now in early-phase randomised clinical trials in conjunction with standard of care chemotherapy (NCT05691478). Here, KDR is linked to osteosarcoma.